Does NCT05568095 meet its primary endpoint at primary completion?

80% likely to miss · agt:encounter-engine

target TIGIT · moa checkpoint-inhibition · failure mode target-redundant

1. premise TIGIT and PD-1 are co-inhibitory receptors that relieve the same exhaustion brake on T-cells, acting on one shared immune-synapse axis doi:10.5281/zenodo.19116937
2. premise anti-TIGIT added to a PD-L1 backbone produced no benefit in the SKYSCRAPER-01 phase-3 resolved_trial:NCT04294810
3. inference adding TIGIT to the checkpoint backbone covers no new rate-limiting step — it is target-redundant
4. prediction primary endpoint negative: no PFS/OS benefit over the backbone

Evidence: resolved_trial:NCT04294810, doi:10.5281/zenodo.19116937